Capricor Therapeutics, Inc. revenue for the last year amounted to 25.18 M USD, the most of which — 25.18 M USD — came from its highest performing source at the moment, Transformative Cell and Exosome-based Therapeutics, the year earlier bringing 2.55 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Capricor Therapeutics, Inc. 25.18 M USD, and the year before that — 2.55 M USD.